NCT04279847
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms treatment 1 recruiting NCT03212053
Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET) No drug interventions screening Not Available completed NCT06218628
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition treatment 1 recruiting NCT00433862
Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders No drug interventions Not Available Not Available completed NCT00586651
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis treatment 2 completed NCT02158858
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis treatment 1 / 2 active_not_recruiting NCT01467661
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia treatment 3 completed NCT01816256
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms No drug interventions screening Not Available completed NCT01352585
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® Not Available Not Available completed NCT01214915
Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia treatment 3 completed NCT06541249
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial treatment 2 not_yet_recruiting NCT01198717
Pediatric Disease Registry in Essential Thrombocythaemia (ET) No drug interventions Not Available Not Available completed NCT04243122
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients prevention 2 completed NCT02577926
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia treatment 2 active_not_recruiting NCT03625895
Agrylin Drug Use-Result Survey No drug interventions Not Available Not Available completed NCT06514807
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients treatment 3 recruiting NCT01230775
Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia prevention 3 completed NCT00413634
The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) treatment 2 completed NCT01065038
Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Not Available 3 completed NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant No drug interventions treatment 2 recruiting NCT06378437
A Study of GLB-001 in Patients With Myeloid Malignancies No drug interventions treatment 1 recruiting NCT06456346
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) treatment 3 recruiting NCT06150157
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms No drug interventions treatment 1 recruiting NCT06079879
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) treatment 3 recruiting NCT00489203
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer supportive_care 2 completed NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy treatment 1 completed NCT00715247
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes No drug interventions Not Available Not Available completed NCT02897297
Myeloproliferative Neoplastic Diseases Observatory From Brest No drug interventions Not Available Not Available recruiting NCT01998828
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia treatment 2 terminated NCT04644211
Ruxolitinib in Thrombocythemia and Polycythemia Vera treatment 2 recruiting NCT05482971
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET treatment 2 recruiting NCT03745378
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) No drug interventions Not Available Not Available completed NCT04254978
Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) treatment 2 completed NCT05025488
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm treatment 1 recruiting NCT02962388
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line treatment 2 / 3 terminated NCT04051307
Dual Vaccine Trial in Myeloproliferative Neoplasms No drug interventions treatment 1 / 2 completed NCT02076815
Anagrelide Retard in Essential Thrombocythemia treatment 3 completed NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction treatment 1 completed NCT01787552
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF treatment 1 / 2 completed NCT03116542
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia No drug interventions diagnostic Not Available unknown_status NCT03878199
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms treatment 1 / 2 recruiting NCT00666549
Research Tissue Bank No drug interventions Not Available Not Available completed NCT03907436
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase No drug interventions treatment Not Available completed NCT01384513
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies treatment 2 completed NCT00397813
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders treatment 2 completed NCT04285086
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance treatment 3 active_not_recruiting NCT06063486
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms No drug interventions treatment 2 recruiting NCT03862157
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT05123365
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms treatment 1 / 2 recruiting NCT01520220
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms treatment 1 completed NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies treatment 2 completed NCT05882773
Asian Myeloproliferative Neoplasm (MPN) Registry No drug interventions Not Available Not Available recruiting NCT06371573
Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms No drug interventions Not Available Not Available completed NCT03869476
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. No drug interventions diagnostic Not Available recruiting NCT05198960
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms prevention 3 recruiting NCT00588991
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders treatment 1 active_not_recruiting NCT00227591
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis treatment 2 completed NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Not Available Not Available completed NCT00866762
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia treatment 2 unknown_status NCT06552429
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET No drug interventions treatment 2 not_yet_recruiting NCT00445744
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome treatment Not Available completed NCT03566446
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms No drug interventions treatment 1 completed NCT03289910
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia treatment 2 active_not_recruiting NCT00745550
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis treatment 1 / 2 completed NCT02760238
Myeloproliferative Neoplasms (MPNs) Patient Registry No drug interventions Not Available Not Available recruiting NCT00047190
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia treatment 2 completed NCT00668421
CEP-701 (Lestaurtinib) in Myelofibrosis treatment 1 / 2 unknown_status NCT02823184
Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms No drug interventions Not Available Not Available completed NCT04282187
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms treatment 2 recruiting NCT03232177
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia No drug interventions treatment 4 completed NCT01192347
French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia No drug interventions Not Available Not Available completed NCT00357305
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders treatment 1 completed NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer treatment Not Available completed NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 1 completed NCT00718159
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia treatment 1 completed NCT03121599
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms No drug interventions diagnostic Not Available terminated NCT06361641
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes No drug interventions diagnostic Not Available recruiting NCT04262141
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) treatment 2 active_not_recruiting NCT00039416
Imatinib Mesylate in Treating Patients With Myelofibrosis treatment 2 completed NCT01831635
Myeloproliferative Neoplasms: an In-depth Case-control Study No drug interventions Not Available Not Available completed NCT01387763
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms treatment 3 completed NCT01970930
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients No drug interventions Not Available Not Available completed NCT02663648
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders No drug interventions Not Available Not Available withdrawn NCT00052520
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation treatment 1 / 2 completed NCT02611973
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia treatment 3 unknown_status NCT01243073
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera treatment 2 completed NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer No drug interventions supportive_care Not Available completed NCT02407080
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia treatment 1 completed NCT04942080
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) No drug interventions other Not Available recruiting NCT00666289
Familial Myeloproliferative Disorders No drug interventions Not Available Not Available completed NCT00665067
Correlative Biomarker Study in Patients With Myeloproliferative Disorders No drug interventions Not Available Not Available completed NCT02129101
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies treatment 1 completed NCT02311569
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation treatment 2 completed NCT01014546
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis treatment 1 terminated NCT02124746
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia treatment 2 completed NCT02893410
Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients No drug interventions Not Available Not Available completed NCT00381550
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia treatment 2 completed NCT03972943
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia No drug interventions treatment 0 terminated NCT05223920
Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) treatment 2 completed NCT06351631
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) treatment 3 recruiting NCT02912884
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure No drug interventions Not Available Not Available completed NCT00522574
A Safety Study of XL019 in Adults With Myelofibrosis treatment 1 terminated NCT04081220
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 treatment 2 active_not_recruiting NCT01134120
A Study in Myeloproliferative Disorders treatment 1 completed NCT00567502
Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments No drug interventions Not Available Not Available completed NCT01816022
Myeloproliferative Neoplasms and Bone Structure No drug interventions Not Available Not Available unknown_status